Donna M Neale

The role of Fas mediated apoptosis in preeclampsia

Abstract It has become clear in recent years that apoptosis is a normal process in trophoblast turnover during pregnancy. Increased trophoblast apoptosis has been observed in the placenta of women with preeclampsia, serum from women with preeclampsia has been found to induce increased trophoblast sensitivity to Fas-mediated apoptosis, and serum from women with preeclampsia has elevated levels of various chemokines, growth factors and cytokines that are involved in the regulation of apoptosis. This review highlights the importance of apoptosis in normal placental development and explores the mechanisms whereby Fas-mediated apoptosis may play a role in conditions related to abnormal placentation, such as preeclampsia.

Characteristics of preeclampsia- and eclampsia-related maternal death in rural Haiti

Objective. The maternal mortality ratio in Haiti remains one of the highest in the world at 600/100 000 live births. Preeclampsia- and eclampsia-related complications are one of the leading causes of maternal death. In this resource-limited setting, effective, efficient hospital-based interventions are necessary to reduce this risk. Our objective was to assess the utility of common laboratory and clinical admission data for the determination of preeclampsia- and eclampsia-related maternal death. Study design. We performed an analysis of women presenting to the Hôpital Albert Schweitzer with preeclampsia and eclampsia during a 3-year period. Factors analyzed were: maternal age, parity, gestational age, hematocrit, serum creatinine, urine protein, systolic and diastolic blood pressure, intrauterine fetal death (IUFD), coma on arrival, and address (residence within or outside hospital catchment area). Stepwise logistic regression identified factors predictive of maternal mortality. Results. Preeclampsia/eclampsia affected 423 of 2295 deliveries (18%) and resulted in 19 deaths. Multivariate analysis identified the following predictors of maternal mortality: IUFD (RR 7.57; 95% CI 2.76–12.69), eclampsia (RR 6.91; 95% CI 2.08–12.64), and oliguria (RR 5.39; 95% CI 1.80–10.69). Conclusion. In this setting, traditional admission laboratory and clinical tests were not useful in maternal mortality prediction. The analysis highlights clinical characteristics of women at highest risk for maternal death.

Emergency Room Utilization After Medically Complicated Pregnancies: A Medicaid Claims Analysis

BACKGROUND Women with pregnancy complications benefit from closer monitoring postpartum and beyond. Increased postpartum emergency room (ER) use may indicate unmet need for outpatient obstetrics and primary care. The purpose of this study was to evaluate whether women with pregnancy complications (gestational diabetes [GDM], gestational hypertension, and preeclampsia) have increased ER use in the first 6 months postpartum, compared with women without these complications. METHODS We conducted a retrospective population-based cohort study using a 2003-2010 Maryland Medicaid managed care claims data set, linked with U.S. Census data. Data included claims for outpatient and ER visits for women aged 12-45 years who were continuously enrolled in Medicaid for at least 100 days of pregnancy and 90 days postpartum. We used logistic regression to calculate the association between pregnancy complications and having ≥1 ER visit in the 6 months postpartum. RESULTS We identified 26,074 pregnancies, of which 20% were complicated by GDM, gestational hypertension, or preeclampsia. Of these complicated pregnancies, 42.1% had GDM, 35.4% had gestational hypertension, and 42.5% had preeclampsia (diagnoses were not mutually exclusive). In the 6 months postpartum, 25% of women had ≥1 ER visits. Of the complicated pregnancy group, 27.7% had ≥1 ER visit, versus 23.6% of the comparison group (p<0.0001). In adjusted analyses, women with a pregnancy complication were more likely to have ≥1 ER visit compared with women without these complications (odds ratio [OR]1.14, 95% confidence interval [CI] 1.05-1.23). The strength of association was highest in women under age 25 (OR 1.20, 95% CI 1.09-1.33). Preconception medical comorbidities (type 2 diabetes, chronic hypertension, obesity, asthma, mental health, and substance abuse diagnoses) were also strongly associated with postpartum ER use (OR 1.61, 95% CI 1.51-1.73). CONCLUSIONS Pregnancy complications increased ER utilization during the 6 months postpartum, especially among women under age 25 years. Interventions that improve discharge planning and early postpartum care may decrease ER use.

Use of pharmacotherapies for smoking cessation: analysis of pregnant and postpartum Medicaid enrollees.

BACKGROUND The Affordable Care Act requires state Medicaid programs to cover pharmacotherapies for smoking cessation without cost sharing for pregnant women. Little is known about use of these pharmacotherapies among Medicaid-enrolled women. PURPOSE To describe the prevalence of prescription fills for smoking-cessation pharmacotherapies during pregnancy and postpartum among Medicaid-enrolled women and to examine whether certain pregnancy complications or copayments are associated with prescription fills. METHODS Insurance claims data for women enrolled in a Medicaid managed care plan in Maryland and who used tobacco during pregnancy from 2003 to 2010 were obtained (N=4,709) and analyzed in 2014. Descriptive statistics were used to calculate the prevalence of smoking-cessation pharmacotherapy use during pregnancy and postpartum. Generalized estimating equations were employed to examine the relationship of pregnancy complications and copayments with prescription fills of smoking-cessation pharmacotherapies during pregnancy and postpartum. RESULTS Few women filled any prescription for a smoking-cessation pharmacotherapy during pregnancy or postpartum (2.6% and 2.0%, respectively). Having any smoking-related pregnancy complication was positively associated with filling a smoking-cessation pharmacotherapy prescription during pregnancy (OR=1.69, 95% CI=1.08, 2.65) but not postpartum. Copayments were associated with significantly decreased odds of filling any prescription for smoking-cessation pharmacotherapies in the postpartum period (OR=0.38, 95% CI=0.22, 0.66). CONCLUSIONS Smoking-related pregnancy complications and substance use are predictive of filling a prescription for pharmacotherapies for smoking cessation during pregnancy. Low use of pharmacotherapies during pregnancy is consistent with clinical guidelines; however, low use postpartum suggests an unmet need for cessation aids in Medicaid populations.

Development and Applications of an Outcomes Assessment Framework for Care Management Programs in Learning Health Systems

Purpose: To develop and apply an outcomes assessment framework (OAF) for care management programs in health care delivery settings. Background: Care management (CM) refers to a regimen of organized activities that are designed to promote health in a population with particular chronic conditions or risk profiles, with focus on the triple aim for populations: improving the quality of care, advancing health outcomes, and lowering health care costs. CM has become an integral part of a care continuum for population-based health care management. To sustain a CM program, it is essential to assure and improve CM effectiveness through rigorous outcomes assessment. To this end, we constructed the OAF as the foundation of a systematic approach to CM outcomes assessment. Innovations: To construct the OAF, we first systematically analyzed the operation process of a CM program; then, based on the operation analysis, we identified causal relationships between interventions and outcomes at various implementation stages of the program. This set of causal relationships established a roadmap for the rest of the outcomes assessment. Built upon knowledge from multiple disciplines, we (1) formalized a systematic approach to CM outcomes assessment, and (2) integrated proven analytics methodologies and industrial best practices into operation-oriented CM outcomes assessment. Conclusion: This systematic approach to OAF for assessing the outcomes of CM programs offers an opportunity to advance evidence-based care management. In addition, formalized CM outcomes assessment methodologies will enable us to compare CM effectiveness across health delivery settings.